Develops and patents drug delivery technologies to improve oral absorption of active pharmaceutical ingredients (APIs). Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 9.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 5% of them.
Analysts' average target sits 62% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $706K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 15 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $11.9M against $706K in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 62% above the average analyst price target.
On our five-subject report card, LEXX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LEXX is a high-risk stock — not yet profitable, and its future rides on its product catching on.